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Mutations in LRRK2 cause autosomal dominant Parkinson’s disease (PD). LRRK2 encodes a multi-domain pro-
tein containing GTPase and kinase domains, and putative protein–protein interaction domains. Familial PD
mutations alter the GTPase and kinase activity of LRRK2 in vitro. LRRK2 is suggested to regulate a number of
cellular pathways although the underlying mechanisms are poorly understood. To explore such mechanisms,
it has proved informative to identify LRRK2-interacting proteins, some of which serve as LRRK2 kinase sub-
strates. Here, we identify common interactions of LRRK2 with members of the dynamin GTPase superfamily.
LRRK2 interacts with dynamin 1–3 that mediate membrane scission in clathrin-mediated endocytosis and
with dynamin-related proteins that mediate mitochondrial fission (Drp1) and fusion (mitofusins and OPA1).
LRRK2 partially co-localizes with endosomal dynamin-1 or with mitofusins and OPA1 at mitochondrial mem-
branes. The subcellular distribution and oligomeric complexes of dynamin GTPases are not altered by modulat-
ing LRRK2 in mouse brain, whereas mature OPA1 levels are reduced in G2019S PD brains. LRRK2 enhances
mitofusin-1 GTP binding, whereas dynamin-1 and OPA1 serve as modest substrates of LRRK2-mediated phos-
phorylation in vitro. While dynamin GTPase orthologs are not required for LRRK2-induced toxicity in yeast,
LRRK2 functionally interacts with dynamin-1 and mitofusin-1 in cultured neurons. LRRK2 attenuates neurite
shortening induced by dynamin-1 by reducing its levels, whereas LRRK2 rescues impaired neurite outgrowth
induced by mitofusin-1 potentially by reversing excessive mitochondrial fusion. Our study elucidates novel
functional interactions of LRRK2 with dynamin-superfamily GTPases that implicate LRRK2 in the regulation
of membrane dynamics important for endocytosis and mitochondrial morphology.
INTRODUCTION
Mutations in the leucine-rich repeat kinase 2 (LRRK2, PARK8)
gene are a common cause of autosomal dominant familial Par-
kinson’s disease (PD) and common variation within the LRRK2
locus is associated with an increased risk of idiopathic PD (1–3).
Despite the major importance of LRRK2 in the pathogenesis of
PD, the biological function of LRRK2 and the mechanisms
by which familial mutations precipitate neurodegeneration in
PD remain poorly understood (4). The LRRK2 gene encodes a
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large multi-domain protein containing a Ras-of-complex (Roc)
GTPase domain in tandem with a C-terminal-of-Roc (COR)
domain together with a protein kinase domain with similarity
to the receptor-interacting protein kinase family (5). LRRK2
additionally contains multiple repeat domains that may mediate
protein–protein interactions, including N-terminal LRRK2-
specific, ankyrin and leucine-rich and C-terminal WD40 repeat
domains. LRRK2 displays GTPase and kinase activity in vitro
and PD-associated mutations can either enhance kinase activity
(G2019S) or impair GTP hydrolysis activity (R1441C/G/H,
Y1699C) (6–14). Although familial mutations have divergent
effects on LRRK2 enzymatic activity, the overexpression of
LRRK2 familial mutants commonly enhances neuronal toxicity
including inhibition of neurite outgrowth and induction of apop-
totic cell death (4,7,13,15–17). The mechanisms regulating the
neurotoxic actions of LRRK2 are not fully understood although
kinase activity is required for the pathogenic effects of the
G2019S mutation in cultured neurons and in rodents (7,16,18,19).
GTPase activity also contributes to LRRK2-dependent neuronal
toxicity (14,16,20–23).
In attempting to explain the physiological function and
neurotoxic actions of LRRK2, a number of cellular pathways,
processes and/or organelles have been implicated (4). LRRK2
has been shown to regulate synaptic vesicle trafficking (24,25),
endocytosis and exocytosis (14,25,26), Golgi complex integrity
(21,27), the actin cytoskeleton and microtubule networks (28,29),
the autophagy–lysosomal pathway (14,30–33), protein sorting
and translation (34,35) and mitochondrial morphology and activ-
ity (36–38) through as yet unclear mechanisms. The seemingly
diverse effects regulated by LRRK2 in mammalian cells are sup-
ported by its broad subcellular distribution with enrichment of
LRRK2 upon multiple intracellular membranous and vesicular
structures including endosomes, lysosomes, mitochondria, micro-
tubule transport vesicles, lipid rafts, the Golgi complex, the
endoplasmic reticulum and synaptosomes (24,39,40). Such a
widespread distribution of LRRK2 could suggest a general
housekeeping function in regulating membrane biogenesis, dy-
namics and/or trafficking within neurons.
To explore the molecular basis for the normal and pathogenic
actions of LRRK2 in neurons, it has been informative to identify
interacting proteins and kinase substrates since the domain
structure of LRRK2 implies that it most likely functions as a
complex protein scaffold to regulate cellular signaling pathways
in a kinase- and/or GTPase-dependent manner (4). Although
a number of putative substrates of LRRK2 kinase activity have
so far been identified in vitro and in invertebrate models (9,21,
22,25,28,41,42), validation of LRRK2-mediated substrate phos-
phorylation in mammalian cells is presently lacking (43,44).
LRRK2-interacting proteins have also been identified that
have provided important insight into the regulation of LRRK2
GTPase activity (i.e. ARHGEF7 and ArfGAP1) (21,22,45), sta-
bility/metabolism (i.e. CHIP and Hsp90) (46,47) and subcellular
localization (i.e. 14-3-3 proteins) (48). Interacting proteins also
provide a basis for the observed effects of LRRK2 on micro-
tubule network dynamics (i.e. b-tubulin) (28), actin cytoskel-
eton dynamics (i.e. moesin) (29), mitochondrial dynamics (i.e.
Drp1) (49,50) and synaptic vesicle mobility and endocytosis
(i.e. Rab5b and endophilin A, etc.) (25,26). The detailed bio-
chemical and cellular characterization of such protein–protein
interactions is important for understanding the full repertoire
of actions exerted by LRRK2 in mammalian cells under normal
and pathological conditions.
Here, we identify and functionally characterize the novel
interaction of LRRK2 with multiple members of the dynamin
superfamily of large GTPases, including proteins regulating
endocytosis and mitochondrial dynamics. Our data implicate
LRRK2 in the regulation of membrane dynamics important for
endocytosis and mitochondrial morphology through a common
interaction with dynamin-superfamily GTPases. Moreover, we
describe a useful pipeline of LRRK2-related assays that can
be employed for the rigorous functional validation of LRRK2-
interacting proteins.
RESULTS
LRRK2 commonly interacts with members of the dynamin
GTPase superfamily
To identify novel interacting proteins for LRRK2, we performed
a yeast two-hybrid screen using an adult human brain cDNA
library as prey with the N-terminal region (residues 1–500)
of human LRRK2 as bait. We identified human dynamin-1
(Dnm1) as a putative interacting partner of LRRK2 (data not
shown). Dnm1 has recently been identified as a putative LRRK2-
interacting protein in a mass spectrometry-based screen of brain
synaptosomes, although verification of this interaction was not
provided (24). Dnm1 is an 864 amino acid neuronal-specific
GTPase that plays an important role in regulating clathrin-
mediated endocytosis by mediating membrane scission events
(51–53). We and others have previously described a role for
LRRK2 in regulating synaptic vesicle endocytosis and exocyt-
osis and thus we elected to further explore the potential relation-
ship between LRRK2 and Dnm1 (14,24,26). The interaction of
these two proteins was first assessed by co-immunoprecipitation
(co-IP) analysis in HEK-293T cells exogenously expressing
FLAG-tagged LRRK2 and GFP-tagged Dnm1. Following IP
of full-length LRRK2, we detect a clear interaction with full-
length Dnm1 (Fig. 1A). Dnm1 belongs to the dynamin superfam-
ily of large GTPases whose members notably include classical
dynamins (i.e. Dnm1, Dnm2 and Dnm3) and dynamin-related
proteins (i.e. dynamin-related protein 1 [Drp1], optic atrophy
protein 1 [OPA1] and mitofusin [Mfn] protein families) (52),
whereas classical dynamins mediate vesicle scission events at
the plasma membrane and trans-Golgi network to regulate endo-
cytosis, dynamin-related proteins are involved in mitochondrial
membrane fission (i.e. Drp1) and fusion (i.e. Mfn1, Mfn2 and
OPA1) events to regulate mitochondrial dynamics (52–54).
To determine whether LRRK2 broadly interacts with members
of the dynamin superfamily, we compared the interaction of
LRRK2 with the classical dynamins, Dnm1, Dnm2 and Dnm3,
by co-IP in HEK-293T cells expressing FLAG-tagged LRRK2
and full-length HA-tagged Dnm1-3. We detect a common inter-
action of LRRK2 with Dnm1, Dnm2 and Dnm3 (Fig. 1B).
LRRK2 has also been implicated in regulating mitochondrial
activity and morphology (36,37,49,50). Accordingly, we asked
whether LRRK2 interacts with the dynamin-related proteins,
Drp1, Mfn1, Mfn2 and OPA1. The interaction of LRRK2 with
dynamin-related proteins was assessed by co-IP in HEK-293T
cells expressing FLAG-tagged LRRK2 and Myc-tagged Drp1,
Mfn1, Mfn2 or OPA1. Following IP of full-length Drp1, Mfn1,
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Mfn2 and OPA1, we detect a robust interaction with full-length
LRRK2 (Fig. 1C). In the reverse experiment, IP of full-length
LRRK2 reveals an interaction with Drp1, Mfn1, Mfn2 and
OPA1 (Fig. 1D–F). Disruption of the GDP/GTP-binding cap-
acity of Drp1 and Mfn1 by mutating a critical lysine residue in
the conserved guanine nucleotide phosphate-binding motif
(K38A in Drp1 and K88T in Mfn1) does not alter the degree of
interaction with LRRK2 (Fig. 1D and E). Expression of full-
length OPA1 gives rise to an unprocessed full-length form
(FL-OPA1) and processed large (L-OPA1) and short (S-OPA1)
mature forms by sequential N-terminal proteolytic cleavage of
a mitochondrial-targeting sequence (MTS) and an adjacent trans-
membrane helix, respectively (Fig. 1C) (55). LRRK2 selectively
interacts with the mature L-OPA1 form lacking the MTS
(Fig. 1F), which is known to be anchored to the mitochondrial
inner membrane via its N-terminal transmembrane helix (55).
We next sought to verify the interaction of LRRK2 and
dynamin GTPases in vivo. LRRK2 interacts with Drp1, Dnm1
and OPA1 (particularly L-OPA1) in whole brain extracts
derived from wild-type (WT) mice following immunoprecipita-
tion with a LRRK2-specific monoclonal antibody (N241A/34),
whereas Drp1, Dnm1 and OPA1 are immunoprecipitated to a
lesser or negligible extent in extracts derived from LRRK2
knockout mice (Fig. 1G). An interaction of LRRK2 with Mfn2
could not be demonstrated, whereas we are not able to reliably
detect Mfn1 in mouse brain using currently available antibodies
(data not shown).
To explore the effects of PD-associated mutations on the inter-
action of LRRK2 with Dnm1, Mfn1 and OPA1, we conducted
co-IP experiments in HEK-293T cells expressing FLAG-tagged
LRRK2 variants with either GFP-tagged Dnm1 or Myc-tagged
Mfn1 and OPA1. Compared with WT LRRK2, the familial PD
mutations R1441C, Y1699C and G2019S do not significantly
alter the interaction of LRRK2 with Dnm1 (Fig. 1H), Mfn1
(Fig. 1I) or OPA1 (Supplementary Material, Fig. S1B). To iden-
tify the domain of LRRK2 that interacts with selected dyna-
min GTPases, co-IP assays were conducted in cells expressing
various deletion mutants of LRRK2 together with HA-tagged
Dnm1 or Myc-tagged Mfn1 and OPA1. Following IP of LRRK2
deletion mutants we find that Dnm1 modestly interacts with mul-
tiple LRRK2 domains, with particular enrichment for residues 1–
480(containingLRRK2-specificandarmadillo repeats), 480–895
(containing ankyrin repeats), 895–1503 (containing LRRand Roc
GTPase domains) and 1534–1857 (containing the COR domain)
of LRRK2 (Fig. 1J). OPA1 preferentially interacts with full-length
LRRK2 but not with isolated domains of LRRK2 (Supplementary
Material, Fig. S1A), suggesting that the intact full-length protein
is required for this interaction. Mfn1 interacts selectively with
N-terminal (residues 1–480 and 480–895) and C-terminal (resi-
dues 2125–2527 containing WD40 repeats) regions of LRRK2
(Fig. 1K), known to mediate protein–protein interactions. Col-
lectively, these data reveal that LRRK2 commonly interacts
with members of the dynamin superfamily in mammalian cells
and brain.
LRRK2 co-localizes with dynamin-1 in endosomal
compartments
To further characterize the interaction of LRRK2 with dynamin
GTPases, and where in cells these interactions might occur, we
assessed their co-localization in mammalian cells by immuno-
cytochemistry and confocal microscopy. We have previously
shown that LRRK2 partly localizes to clathrin-coated endosomes
by electron microscopy and is enriched within microsomal and
synaptosomal membranes by subcellular fractionation in rodent
brain (39). Since Dnm1 is known to localize to early endosomes
where it regulates clathrin-mediated endocytosis (52), we first
sought to determine which endosomal compartments co-localize
with LRRK2. Co-expression of FLAG-LRRK2 with RFP-Rab5
and GFP-Rab7 in rat primary cortical neurons reveals a high
degree of localization of LRRK2 with Rab5-positive early endo-
somes (Rcoloc ¼ 0.79+ 0.04) but a smaller degree of co-local-
ization with Rab7-positive late endosomes (Rcoloc ¼ 0.41+
0.06) (Supplementary Material, Fig. S2). We compared the
effects of familial PD mutations on the co-localization of
LRRK2 with Rab5 and Rab7 but do not observe significant dif-
ferences between WT, R1441C and G2019S variants (Supple-
mentary Material, Fig. S2). These data indicate that LRRK2
preferentially co-localizes with early endosomes, a compart-
ment where Dnm1 is known to prominently reside. Next, we
co-expressed FLAG-LRRK2 variants and RFP-Rab5 together
with HA-tagged Dnm1 plasmids in human SH-SY5Y neural
cells to assess their co-localization. We could observe the
equivalent co-localization of WT and R1441C LRRK2 with
Dnm1 (Rcoloc: 0.634+ 0.055 for WT or 0.729+ 0.032 for
R1441C) with significantly increased co-localization of Dnm1
with the G2019S variant (Rcoloc: 0.785+ 0.019). We also
observe marked co-localization of Dnm1 with Rab5-positive
early endosomes in the presence or absence of LRRK2 overex-
pression (Rcoloc: 0.584+ 0.061 for control vector; 0.663+
0.023 for WT LRRK2; 0.686+ 0.032 for R1441C LRRK) but
with significantly reduced co-localization due to G2019S LRRK2
(Rcoloc: 0.504+0.039) (Fig. 2). Taken together, these data indi-
cate the partial co-localization of LRRK2 and Dnm1 in or adjacent
to early endosomal compartments, suggesting that these proteins
most likely interact at the cytoplasmic face of endosomal vesicles.
The familial G2019S mutation increases the co-localization of
LRRK2 with Dnm1 but reduces the proportion of Dnm1 on early
endosomes.
LRRK2 co-localizes with dynamin-related GTPases at
mitochondrial membranes
We have previously shown that LRRK2 localizes in part to the
mitochondrial outer membrane and matrix compartment in
mammalian cells and rodent brain by confocal microscopy, sub-
mitochondrial fractionation and electron microscopy (12,39).
To explore the co-localization of LRRK2 with dynamin-related
GTPases, we co-expressed FLAG-LRRK2 and Myc-tagged
Drp1, Mfn1, Mfn2 and OPA1 together with the mitochondrial
marker, mito-RFP, in primary cortical neurons. Drp1 normally
localizes diffusely within the cytoplasm but can translocate to
the mitochondrial outer membrane regulated by posttranslational
modifications to mediate mitochondrial fission (56). LRRK2 par-
tially co-localizes with WT and K38A Drp1 (Rcoloc: 0.345+
0.014 for WT or 0.285+0.039 for K38A Drp1) mostly within
the cytoplasm but to a small extent upon RFP-positive mitochon-
dria in neurons (Fig. 3). Mfn1 and Mfn2 are localized to the outer
membrane of mitochondria where they regulate outer membrane
fusion, whereas OPA1 is associated with the mitochondrial inner
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Figure 1. LRRK2 commonly interacts with members of the dynamin GTPase superfamily. (A) FLAG-tagged human LRRK2 interacts with GFP-tagged human Dnm1
following immunoprecipitation (IP) with anti-FLAG antibody from HEK-293T cells. (B) HA-tagged mouse Dnm1, Dnm2 and Dnm3 interact with FLAG-LRRK2
following IP with anti-HA antibody. (C) Myc-tagged Drp1, Mfn1, Mfn2 and OPA1 interact with FLAG-LRRK2 following IP with anti-myc antibody. (D–F)
FLAG-LRRK2 interacts with (D) Myc-tagged WT and K38A Drp1, (E) WT and K88T Mfn1 and (F) Mfn2 and OPA1, following IP with anti-FLAG antibody
from HEK-293T cells. (G) LRRK2 interacts with Drp1, Dnm1 and OPA1 in whole brain extracts from WT mice but not LRRK2 knockout (KO) mice following
IP with anti-LRRK2 antibody (clone N241A/34). Data are representative of two-independent experiments. (H) Dnm1-GFP and (I) Myc-Mfn1 interact with WT
and PD-associated mutant forms of FLAG-LRRK2 following IP with anti-FLAG antibody from HEK-293T cells. Densitometric analysis reveals no significant
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membrane and intermembrane space and regulates fusion of
the inner membrane (54). LRRK2 partially co-localizes with WT
and K88T Mfn1 (Rcoloc: 0.227+0.035 for WT or 0.235+
0.051 for K88T Mfn1), Mfn2 (Rcoloc: 0.318+ 0.029) and
OPA1 (Rcoloc: 0.203+ 0.053) upon RFP-positive mitochon-
dria (Fig. 3). As expected, Mfn1, Mfn2 and OPA1 localization
is enriched upon or in close proximity to mito-RFP-positive
mitochondria (Fig. 3), consistent with their known association
with mitochondrial membranes. Collectively, these data indicate
the partial co-localization of LRRK2 with dynamin-related
GTPases and suggest that LRRK2 and Drp1 most likely interact
within the cytoplasm whereas LRRK2 and Mfn1, Mfn2 and
OPA1 interact at or adjacent to mitochondrial membranes.
Impact of LRRK2 expression on subcellular distribution
and native complexes of dynamin GTPases in mouse brain
To begin to explore the potential functional interaction of
LRRK2 with dynamin GTPases, we examined the impact of
the common G2019S mutation in LRRK2 on the subcellular dis-
tribution of endogenous dynamin GTPases in adult mouse brain.
Subcellular fractionation was conducted on cerebral cortex
tissue derived from human G2019S LRRK2 transgenic and non-
transgenic mice (Fig. 4A). Dnm1 is broadly distributed across all
fractions but with enrichment in the heavy membrane (P2), light
membrane/microsomal (P3) and synaptosomal membrane (LP1)
fractions. Drp1 is also widely distributed across soluble and
membrane fractions with enrichment in the soluble S1, S2 and
S3 fractions (Fig. 4A). Mfn2 and OPA1 are enriched within
the heavy membrane/mitochondrial (P2), synaptosomal mem-
brane (LP1) and soluble S1 fractions (Fig. 4A). For comparison,
LRRK2 is enriched in the light membrane/microsomal (P3) frac-
tion and is detected in the synaptosomal (LP1), synaptic vesicle
(LP2) and heavy (P2) membrane fractions and soluble (S1 and
S2) fractions (Fig. 4A). LRRK2 co-fractionates with Dnm1,
Drp1, Mfn2 and OPA1 in the synaptosomal (LP1) and heavy
(P2) membrane fractions, and with Dnm1 and Drp1 in the light
membrane (P3) fraction (Fig. 4A) of mouse brain. However,
the subcellular fractionation profiles of Dnm1, Drp1, Mfn2
and OPA1 in mouse brain are not altered in human G2019S
LRRK2 transgenic mice compared with their non-transgenic
littermates (Fig. 4A). We are unable to reliably assess the subcel-
lular distribution of Mfn1 in these mouse brain extracts due to a
lack of sufficiently specific antibodies for detecting endogenous
Mfn1. These data reveal that the pathogenic G2019S mutation in
human LRRK2 does not influence the subcellular distribution of
Dnm1, Drp1, Mfn2 and OPA1 in the adult mouse brain.
Dynamin GTPases areknownto function through the formation
of homo-oligomeric complexes to mediate membrane fission or
fusion (52,54). To explore the impact of LRRK2 expression on
the formation of oligomeric complexes by dynamin GTPases,
we conducted native-PAGE analysis on soluble extracts of
cerebral cortex derived from G2019S LRRK2 transgenic and
non-transgenic mice, and LRRK2 knockout (KO) mice and
their WT littermates (Fig. 4B). Dnm1 forms a broad range
of native complexes from 300 kDa to 1 mDa with distinct
complexes at 300, 480 and 800 kDa consistent with a
range of oligomeric species. Drp1 forms a major native complex
of 350–480 kDa in addition to less abundant complexes. OPA1
also forms a broad range of native complexes from 300 to
720 kDa but with a distinct complex centered at 300–
350 kDa. Importantly, these native brain complexes are not
altered by the transgenic overexpression of human G2019S
LRRK2 or by LRRK2 deletion in KO mice compared with
control mice (Fig. 4B). We are not able to reliably detect Mfn2
complexes by native PAGE in these soluble brain extracts
(data not shown). SDS–PAGE analysis conducted in parallel
on these soluble mouse brain extracts reveals that the
steady-state levels of Dnm1, Drp1, Mfn2 and OPA1 are not
altered by modulating LRRK2 expression (Fig. 4C). To further
explore oligomeric complexes of dynamin GTPases, we con-
ducted size-exclusion chromatography on soluble brain extracts
derived from adult WT and LRRK2 KO mice (Fig. 4D and E).
Dnm1 elutes over a broad range (fractions 4–12) with the
majorityofsignalbetween440and669 kDacompatiblewithanoli-
gomeric complex (Fig. 4D). Drp1 elutes over a smaller range (frac-
tions 8–13) with the majority of signal between 158 and 440 kDa
(Fig. 4D). For comparison, LRRK2 broadly elutes within fractions
3–11 with the highest signal centered at 669 kDa compatible with a
dimer-sized LRRK2 complex (Fig. 4E). Importantly, the hydro-
dynamic volumes of Dnm1 and Drp1 under native conditions are
not altered by the absence of LRRK2 expression in KO mice
(Fig. 4D). We are not able to reliably detect Mfn2 or OPA1 com-
plexes by size-exclusion chromatography in these soluble brain
extracts (data not shown). Collectively, these data indicate that
LRRK2 expression does not influence the formation of endogenous
Dnm1,Drp1orOPA1nativeproteincomplexesor the total levelsof
these proteins in the mouse brain.
Reduced levels of mature OPA1 in G2019S PD brains
We next sought to determine the impact of G2019S LRRK2 ex-
pression on the steady-state levels of Dnm1, Drp1, Mfn2 and
OPA1 in the human brain. Accordingly, soluble extracts
derived from the frontal cortex of G2019S mutant or idiopathic
PD brains and normal control brains were subjected to western
blot analysis for each protein (Fig. 5). We observe no significant
differences in the steady-state levels of Dnm1, Drp1 and Mfn2 in
G2019S mutant or idiopathic PD brains compared with control
brains (Fig. 5). However, we observe a significant marked reduc-
tion of the mature short form of OPA1 (S-OPA1) but not the long
form (L-OPA1) in G2019S mutant PD brains compared with
control brains, and a non-significant reduction of S-OPA1 in
idiopathic PD brains (Fig. 5). Our data demonstrate that the
differences in the interactions of Dnm1 or Mfn1 with R1441C, Y1699C and G2019S LRRK2 compared with WT LRRK2. Data represent the level of interaction of
Dnm1 or Mfn1 with LRRK2 expressed as a percent of the interaction with WT LRRK2. The levels of Dnm1 or Mfn1 IP were first normalized to their respective input
levels, and then further normalized to LRRK2 IP levels. Bars represent the mean+SEM (n ¼ 3 experiments). n.s., non-significant. (J and K) Domainmapping reveals
the interaction of HA-Dnm1 with full-length (WT) LRRK2, residues 1–480, 480–895, 981–1503 and 1534–1857 of LRRK2, and to a lesser extent other LRRK2
domains (J), whereas Myc-Mfn1 interacts with full-length LRRK2 and residues 1–480, 480–895 and 2125–2527 of LRRK2 (K) following IP with anti-FLAG anti-
body. (K) Domain organization of LRRK2 deletion mutants is indicated. Data are representative of at least three-independent experiments.
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Figure 2. LRRK2 partially co-localizes with Dnm1 at early endosomes in neural cells. (A–C) Confocal fluorescence microscopy reveals the partial co-localization of
FLAG-tagged human LRRK2 (WT, G2019S and R1441C) with HA-tagged human Dnm1 at RFP-Rab5-positive early endosomal vesicles in human SH-SY5Y neural
cells. Cytofluorograms and co-localization coefficients (Rcoloc; mean+SEM, n ¼ 10–12 cells/condition) reveal the extent of co-localization between LRRK2 and
Dnm1 fluorescence signals. (A–D) Confocal images, cytofluorograms and co-localization coefficients revealing the effect of overexpressing human LRRK2 variants
on the degree of co-localization of Dnm1 and Rab5, relative to control cells transfected with empty vector (pcDNA3.1). Confocal images are taken from a single
z-plane at 0.1 mm thickness. Images are representative of multiple cells from at least two-independent transfection experiments. Scale bars: 10 mm. (E and F)
Graphs indicating co-localization coefficients (mean+SEM, n ¼ 10–12 cells) for (E) Dnm1 and LRRK2 variants and (F) Dnm1 and Rab5. The G2019S mutation
significantly increases the co-localization of LRRK2 with Dnm1 (E), and reduces the co-localization of Dnm1 with Rab5-positive endosomes (F). ∗P , 0.05 and
∗∗P , 0.01 by one-way ANOVA with Newman–Keuls post hoc analysis, as indicated. n.s., non-significant.
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pathogenic G2019S mutation selectively reduces the steady-
state levels of the mature short form of OPA1 in the human
frontal cortex.
LRRK2 enhances the levels of GTP-bound mitofusin-1
To determine whether the interaction with LRRK2 may serve to
regulate the GTPase activity of dynamin-superfamily members,
and vice versa, we explored the effects of co-expressing LRRK2
and dynamin GTPases on their capacity to bind GTP. To monitor
the steady-state levels of GTP-bound LRRK2 or dynamin
GTPases, we conducted pull-down assays using GTP-agarose
from HEK-293T cell extracts expressing each protein alone or
together. Co-expression with Drp1, Mfn1, Mfn2 or OPA1, but
not with Dnm1, results in a marked yet non-significant increase
in the levels of GTP-bound LRRK2 (Fig. 6). Control experi-
ments confirm the specificity of LRRK2 binding to immobilized
GTP as the T1348N variant of LRRK2 abolishes binding to GTP
Figure 3. LRRK2 partially co-localizes with dynamin-related GTPases at mitochondria in cortical neurons. Confocal fluorescence microscopy reveals the partial
co-localization of FLAG-tagged human LRRK2 with Myc-tagged Drp1 (WT and K38A), Mfn1 (WT and K88T), Mfn2 and OPA1 at mito-RFP-positive mitochondria
in rat primary cortical neurons. Cytofluorograms and co-localization coefficients (Rcoloc; mean+SEM, n ≥ 5 cells) reveal the extent of co-localization of LRRK2
with Drp1, Mfn1, Mfn2 or OPA1 fluorescence signals. The degree of co-localization of Drp1, Mfn1, Mfn2 and OPA1 with mito-RFP fluorescence signals is also
indicated for comparison. Confocal images are taken from a single z-plane at 0.1 mm thickness. Images are representative of multiple neurons from at least
two-independent transfection experiments. Scale bars: 10 mm.
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Figure4. Subcellulardistribution and nativecomplexesof dynaminGTPases are not alteredby LRRK2in mousebrain. (A) Subcellular fractionation ofcerebral cortex
tissue derived from human G2019S LRRK2 transgenic and non-transgenic mice. Dnm1 and Drp1 are broadly distributed across multiple membrane and soluble frac-
tions, whereas Mfn2 and OPA1 are enriched in heavy membrane (P2) and synaptosomal membrane (LP1) fractions. LRRK2 is broadly detected with enrichment in
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(Fig. 6). Of the five dynamin GTPases examined, only Dnm1 and
Mfn1 consistently bind to GTP at detectable levels in this assay
when expressed alone (Fig. 6). Co-expression with LRRK2 fails
to alter the levels of GTP-bound Dnm1, but results in a marked
and significant increase in GTP-bound Mfn1 (Fig. 6). Since
both LRRK2 and dynamin GTPases display GTP hydrolysis ac-
tivity, it was not possible to discriminate their specific functional
effects on each other when incubated together in in vitro assays
measuring the hydrolysis of GTP to GDP (data not shown). Col-
lectively, our data suggest that dynamin-related GTPases enhance
theGTP-bindingcapacityof LRRK2,whereasoppositelyLRRK2
markedly enhances the GTP-binding activity of Mfn1.
Dynamin GTPases are modest substrates of
LRRK2-mediated phosphorylation in vitro
To further characterize the interaction of LRRK2 with dynamin
GTPases, we sought to determine whether they serve as sub-
strates of LRRK2-mediated phosphorylation. In vitro kinase
assays using [33P]-g-ATP with soluble recombinant full-length
LRRK2 variants and each immunopurified (‘on-bead’) dynamin
GTPase reveal a modest increase in the phosphorylation of
Dnm1, Drp1, Mfn1 and OPA1, but not Mfn2, by G2019S LRRK2
compared with WT or kinase-inactive (D1994A) LRRK2 (Fig. 7).
For comparison, we observe robust LRRK2 autophosphorylation
in these kinase assays, and the robust phosphorylation of YFP-
tagged ArfGAP1, a recently identified LRRK2 substrate (Fig. 7)
(21,22). To reduce potential contamination from co-purified
kinases in these assays, we conducted in vitro kinase assays
using recombinant full-length GST-tagged Drp1, Mfn1 and
OPA1 combined with soluble recombinant full-length LRRK2
variants in the absence of Dynabead complexes. In these
assays, we consistently observe the phosphorylation of OPA1
byG2019S LRRK2, butwe fail to observe appreciable phosphor-
ylation of Drp1 and Mfn1 by LRRK2 variants despite detecting
robust phosphorylation of recombinant GST-tagged ArfGAP1
by G2019S LRRK2 as well as LRRK2 autophosphorylation
(Fig. 8). Our data suggest that dynamin GTPases serve as modest
substrates of LRRK2-mediated phosphorylation in vitro, espe-
cially Dnm1 and OPA1, and should therefore be considered as
putative substrates.
Dynamin-related GTPases are not required for
LRRK2-mediated toxicity in yeast
We previously developed a robust model of LRRK2-mediated
toxicity in the baker’s yeast, Saccharomyces cerevisiae, which
exhibits defects in vesicular trafficking (14). The inducible
expression of human LRRK2 fragments in yeast reduces cell via-
bility in a manner dependent on its GTPase domain and GTPase
activity (14). To further explore the functional interaction
between LRRK2 and dynamin GTPases, we assessed the re-
quirement of dynamin orthologs for LRRK2-induced toxicity
in yeast. We obtained haploid yeast knockout strains harboring
deletions of DNM1, FZO1 and MGM1, which encode orthologs
of mammalian Drp1, Mfn1/2 and OPA1, respectively. We also
selected additional yeast knockout strains with deletion of
MDV1 (FIS2) and MDV2 (FIS1) that are required for mitochon-
drial fission together with DNM1, andUGO1 that is required for
mitochondrial fusion together with FZO1 and MGM1. Yeast do
not contain a clear ortholog of mammalian dynamin-1. Yeast
strains were transformed with high-copy galactose-inducible
(GAL1 promoter) expression vectors containing WT human
LRRK2 (residues 1300–2527) or a control empty vector, and
resulting yeast clones were spotted as 5-fold serial dilutions on
solid media containing glucose (LRRK2 ‘repressed’) or galact-
ose (LRRK2 ‘induced’) to assess growth fitness. The expression
of human LRRK2 impairs yeast growth on galactose media
compared with a control empty vector in WT parental yeast
(BY4741) (Fig. 9A). Deletion of mitochondrial fission (DNM1,
MDV1 and MDV2) factors does not influence the level of
LRRK2-induced toxicity in yeast (Fig. 9A). Notably, however,
FZO1, MGM1 and UGO1 knockout strains grow poorly on
galactose-containing media and were refractory to further
analysis.
Since yeast metabolize glucose and galactose primarily through
fermentation, we conducted similar genetic interaction studies on
non-fermentable carbon sources such as glycerol and ethanol that
are metabolized by mitochondrial respiration (oxidative phos-
phorylation). We transformed yeast strains with high-copy
vectors expressing human LRRK2 (residues 1300–2527) from
a constitutive GPD promoter and conducted spotting growth
assays on media containing glucose, galactose, glycerol or
ethanol as the sole carbon source. FZO1, MGM1 and UGO1 de-
letion strains fail to grow on non-fermentable carbon sources
and galactose irrespective of LRRK2 expression indicating
a pronounced defect in mitochondrial respiration (Fig. 9B).
However, the deletion of FZO1, MGM1 and UGO1 does not ap-
preciably influence LRRK2-induced yeast toxicity relative to
WT yeast and a control empty vector on media containing
glucose (Fig. 9B). Similarly, the deletion of DNM1, MDV1 and
MDV2does not alter LRRK2-induced toxicity on media contain-
ing glucose, galactose, glycerol or ethanol as the carbon source
compared with WT yeast (Fig. 9B). Of note, LRRK2-induced
toxicity in WT yeast is similar on fermentable (i.e. glucose
or galactose) and non-fermentable (i.e. glycerol or ethanol)
light membrane/microsomal (P3), synaptosomal LP1 and synaptic vesicle-enriched (LP2) membrane fractions. The distribution of the synaptic vesicle-associated
protein, synaptophysin 1, demonstrates enrichment of membranes in P2, P3, LP1 and LP2 fractions, whereas Mfn2 and OPA1 indicate enrichment of mitochondria
in P2 and LP1 fractions. (B) Native-PAGE and (C) SDS–PAGE analysis of equivalent cerebral cortex extracts derived from human G2019S LRRK2 transgenic (Tg)
and non-transgenic (NTg) mice, and LRRK2 KO and WT mice, revealing similar oligomeric protein complexes for Dnm1, Drp1 and OPA1. (C) LRRK2 antibodies
confirm the absence of LRRK2 in KO mice (mouse-selective N241A/34 antibody) and human G2019S LRRK2 expression in transgenic mice (human-selective
MJFF4/c81-8 antibody; lower band ¼ LRRK2; asterisk indicates non-specific upper band). (D and E) Size-exclusion chromatography on soluble whole brain extracts
from WT and LRRK2 KO mice. Sequential fractions (#1–16, 0.5 ml) and total homogenates (WT or KO) were analyzed by western blotting with antibodies to Dnm1,
Drp1 and LRRK2 (N241A/34), orb-tubulin as a loading control. The elution profile of Dnm1 and Drp1 is similar in WT and KO brains, whereas the elution profile of
individual standards is indicated. LRRK2 antibody (N241A/34) confirms the absence of LRRK2 in KO mice. Blots are representative of duplicate experiments. Mo-
lecular mass markers are indicated in kDa.
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carbon sources, suggesting that mitochondrial respiration is
not critically required for LRRK2-mediated toxicity in yeast
(Fig. 9B). Collectively, these data demonstrate that LRRK2-
induced toxicity in yeast does not require endogenous dynamin-
related GTPases that regulate mitochondrial fission and fusion
processes, or mitochondrial respiration.
LRRK2 attenuates neurite shortening induced by
dynamin-1 by reducing its steady-state levels
LRRK2robustly regulatesneuronalprocesscomplexity inprimary
cultures with the overexpression of PD-associated mutants leading
to reduced neurite length and branching and oppositely deletion or
silencing of LRRK2 enhancing neurite complexity (15,21,29,32).
We therefore sought to determine the functional effects of dy-
namin GTPases on LRRK2-induced neurite shortening. Primary
cortical neurons at days in vitro (DIV) 3 were co-transfected
with combinations of FLAG-LRRK2, GFP-Dnm1 and DsRed-
Max plasmids at a DNA molar ratio of 10:10:1 to morphologic-
ally label transfected neurons (Fig. 10A). At DIV 7, the length
of DsRed-positive neuritic processes was determined for each
condition. Unexpectedly, the overexpression of Dnm1 alone
reduces the length of DsRed-positive neuritic processes by
30%, whereas expression of WT LRRK2 has modest effects
on neurite length, compared with neurons expressing DsRed
alone (Fig. 10B). Unexpectedly, co-expression with WT LRRK2
significantly attenuates neurite shortening induced by Dnm1
(Fig. 10B). Neurite shortening induced by the expression of
K44A-Dnm1, a dominant-negative mutant that inhibits endo-
cytosis, is also significantly attenuated by co-expression with
WT LRRK2 (Supplementary Material, Fig. S3A). To potentially
explain the protective effects of WT LRRK2, we assessed the
steady-state levels of Dnm1-GFP and FLAG-LRRK2 proteins
in cortical cultures under similar conditions. We find that
LRRK2 expression results in a marked reduction of WT and
K44A Dnm1 levels, whereas oppositely K44A Dnm1 but
not WT Dnm1 expression markedly reduces LRRK2 levels
(Fig. 10C and Supplementary Material, Fig. S3B). These data
suggest that LRRK2 attenuates Dnm1-mediated neurite shorten-
ing by reducing the levels of exogenous Dnm1 protein in cortical
Figure 5. Reduced levels of mature S-OPA1 in G2019S mutant PD brains. Western blot analysis of frontal cortex soluble fractions from human control, idiopathic PD
(iPD) or G2019S LRRK2 PD subjects with antibodies to Dnm1, Drp1, OPA1 and Mfn2, or b-tubulin as a protein loading control. Densitometric analysis of Dnm1,
Drp1, OPA1 (L-OPA1 and S-OPA1) and Mfn2 in idiopathic or G2019S PD brains compared with control brains are indicated. The levels of each protein were normal-
ized to b-tubulin levels, and expressed as a percent of control subjects (mean+SEM, n ¼ 4 subjects/group). ∗P , 0.05 by one-way ANOVA with Newman–Keuls
post hoc analysis, as indicated.
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neuronal cultures. Moreover, enhancing (WT Dnm1) or inhibit-
ing (dominant-negative K44A Dnm1) dynamin-dependent
endocytosis similarly leads to impaired neurite outgrowth.
To further understand the effect of LRRK2 on the steady-state
levels of Dnm1, we assessed Dnm1 protein solubility, degrad-
ation and turnover in the presence or absence of LRRK2 in
primary cortical neurons. We demonstrate that LRRK2 ex-
pression does not reduce the steady-state levels of soluble
Dnm1-GFP by promoting its degradation, since prolonged in-
hibition of the proteasome (MG132) or lysosome (bafilomycin
A1) fails to appreciably restore Dnm1-GFP levels (Supplemen-
tary Material, Fig. S4A). LRRK2 expression also fails to alter the
detergent solubility of Dnm1-GFP as revealed by comparing
Triton-soluble and Triton-insoluble (RIPA-soluble) neuronal
extracts (Supplementary Material, Fig. S4A). Finally, we as-
sessed the effect of LRRK2 expression on Dnm1-GFP turnover
by inhibiting new protein synthesis by treatment with cyclohex-
imide over a 24 h period in transfected neuronal cultures.
Dnm1-GFP levels are relatively stable over a 24 h period with
little change in turnover (Supplementary Material, Fig. S4B).
LRRK2 expression fails to alter the rate of Dnm1-GFP turnover
in cortical neurons (Supplementary Material, Fig. S4B). Our
data suggest that the reduction in Dnm1 levels induced by
LRRK2 expression in cortical neurons does not result from
alterations in Dnm1 protein solubility, degradation or turnover.
Drp1-induced neurite shortening is not influenced by
LRRK2
Next, the effects of Drp1 on LRRK2-induced neurite shortening
were assessed. Primary cortical neurons were co-transfected with
combinations of FLAG-LRRK2, Myc-Drp1 and DsRed-Max
Figure 6. LRRK2 enhances the levels of GTP-bound Mfn1. Dynamin GTPases (Dnm1, Drp1, Mfn1, Mfn2 and OPA1) fail to significantly influence the steady-state
levels of FLAG-tagged WT LRRK2 bound to GTP following pull-down assays with GTP-agarose from HEK-293T cell extracts. The specificity of LRRK2 GTP
binding is indicated by the absence of binding of the GDP/GTP-binding-deficient LRRK2 mutant, T1348N (TN). Densitometric analysis reveals significantly enhanced
steady-state levels of Mfn1 but not Dnm1 bound to GTP in the presence of LRRK2. Note that only Mfn1 and Dnm1 reveal detectable GTP binding when expressed alone
compared with Drp1, Mfn2 and OPA1. Molecular mass markers are indicated in kDa. Data represent the level of LRRK2 (left) or Dnm1 and Mfn1 (right) GTP binding
expressed as a percent of the levels of each protein alone. GTP-bound protein levels were normalized to input protein levels. Bars represent the mean+SEM (n ¼ 3
experiments). ∗P, 0.05 or ∗∗P, 0.002 by one-way ANOVA with Newman–Keuls post hoc analysis, as indicated. n.s., non-significant.
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Figure 7. Dynamin GTPases are modestly phosphorylated by LRRK2 in vitro. In vitrokinase assays with [33P]-g-ATP, soluble recombinant full-length FLAG-tagged
LRRK2 variants (WT, G2019S or D1994A) and immunopurified ‘on-bead’ YFP-tagged ArfGAP1 (A), GFP-tagged Dnm1 (B), and Myc-tagged Drp1 (C), Mfn1 (D),
Mfn2 (E) or OPA1 (F), derived by IP from transfected HEK-293T cells. Following kinase reactions, soluble LRRK2 and ‘on-bead’ substrates were separated and
resolved on independent SDS–PAGE gels, as indicated. Western blot analysis with anti-GFP, anti-myc or anti-FLAG antibodies indicate equal loading of
ArfGAP1, Dnm1, Drp1, Mfn1, Mfn2, OPA1 and LRRK2 proteins in each condition. Autoradiographs (33P) reveal the LRRK2-dependent phosphorylation of
ArfGAP1, Dnm1, Drp1, Mfn1 and OPA1, with enhanced phosphorylation by G2019S LRRK2 compared with WT or kinase-inactive D1994A LRRK2. A soluble
eluate from FLAG IPs (derived from non-transfected cells) was used as a control in each assay to assess background 33P incorporation for each substrate. LRRK2
autophosphorylation is also detected in these assays. Blots are representative of at least three-independent kinase experiments.
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plasmids and the length of DsRed-positive neuritic processes
were determined (Fig. 11A). The overexpression of WT or K38A
Drp1 alone significantly reduces neurite lengthby30% with neg-
ligible effects of WT LRRK2 alone, whereas co-expression with
WT LRRK2 fails to influence the effects of WT Drp1 on neurite
length (Fig. 11B). Although Myc-Drp1 protein is detectable by im-
munofluorescence analysis in these cultures (Fig. 11A), it was not
possible to reliably assess the levels of Myc-Drp1 protein by
western blot analysis under similar conditions due to the low ex-
pression of exogenous Drp1 (data not shown). Our data indicate
that LRRK2 does not influence Drp1-mediated neurite shortening
potentially suggesting that Drp1 lies downstream of LRRK2 activ-
ity in a common pathway. Moreover, enhancing (WT Drp1) or
inhibiting (dominant-negative K38A Drp1) mitochondrial fission
similarly leads to impaired neurite outgrowth (Fig. 11B).
Neurite shortening induced by mitofusin-1 is attenuated by
LRRK2
To explore the functional effects of Mfn1 on LRRK2-induced
neurite shortening, we conducted similar assays in primary cor-
tical neurons. Similar to Dnm1 and Drp1, the overexpression of
Mfn1 alone dramatically reduces the length of DsRed-positive
neuritic processes by .40% compared with the expression of
WT LRRK2 or DsRed alone (Fig. 12A and B). Co-expression
with WT LRRK2 partially rescues Mfn1-induced neurite
Figure 8. Recombinant OPA1 is phosphorylated by LRRK2 in vitro. In vitro kinase assays with [33P]-g-ATP, recombinant soluble full-length FLAG-tagged LRRK2
variants (WT, G2019S or D1994A) and recombinant full-length GST-tagged ArfGAP1 (A), Drp1 (B), Mfn1 (C) or OPA1 (D). Western blot analyses with anti-GST
and anti-FLAG antibodies indicate equal loading and positions of ArfGAP1, Drp1, Mfn1, OPA1 and LRRK2 proteins in each condition. Autoradiographs (33P) reveal
the LRRK2-dependent phosphorylation of ArfGAP1 and OPA1, with enhanced phosphorylation by G2019S LRRK2 compared with WT or D1994A LRRK2. A
soluble eluate from FLAG IPs (derived from non-transfected cells) was used as a control in each assay to assess background 33P incorporation for each substrate.
LRRK2 autophosphorylation is also detected in these assays. Blots are representative of at least three-independent kinase experiments.
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shortening (Fig. 12A and B). We conducted similar experiments
using G2019S LRRK2. The overexpression of G2019S LRRK2
alone causes a30% reduction in neurite length, whereas surpris-
ingly, its co-expression with Mfn1 leads to a complete rescue
of Mfn1-induced neurite shortening (Fig. 12A and B). Under
similar conditions, the steady-state levels of exogenous FLAG-
LRRK2 and Myc-Mfn1 proteins in cortical neurons assessed by
western blot analysis are similar when expressed alone or to-
gether, indicating that the effects of these proteins on neurite
length do not result from altered protein levels (Fig. 12C). Our
data indicate thatLRRK2rescues Mfn1-mediatedneurite shorten-
ing potentially by promoting mitochondrial fission and thereby
counteracting excessive mitochondrial fusion induced by Mfn1
expression. Moreover, enhancing mitochondrial fusion (WT
Mfn1, Fig. 12) or inhibiting mitochondrial fission (K38A
Drp1, Fig. 11) similarly result in impaired neurite outgrowth.
DISCUSSION
Here, we identify and functionally validate novel interactions of
LRRK2 with multiple members of the dynamin GTPase
superfamily that are known to regulate membrane dynamics
(52). LRRK2 commonly interacts with the classical dynamins,
Dnm1, Dnm2 and Dnm3, which play an important role in mem-
brane scission during clathrin-mediated endocytosis. LRRK2
also interacts with dynamin-related GTPases that regulate mito-
chondrial membrane fission (Drp1) and fusion (Mfn1, Mfn2 and
OPA1) events. The full-length LRRK2 protein is required for the
interaction with OPA1, whereas multiple N-terminal (LRRK2-
specific, armadillo, ankyrin, LRR and Roc domains) and C-
terminal (COR and WD40 domains) domains of LRRK2 are suf-
ficient for the interaction with Dnm1 or Mfn1. PD-associated
mutations located within the Roc (R1441C), COR (Y1699C)
and kinase (G2019S) domains of LRRK2 do not influence the
interaction with Dnm1, Mfn1 or OPA1. LRRK2 partially co-
localizes with Dnm1 upon early endosomal membranes, with
Drp1 mostly in the cytoplasm, and with Mfn1, Mfn2 and
OPA1 at mitochondrial membranes of neural cells. Furthermore,
dynamin GTPases co-fractionate with endogenous LRRK2 in
synaptosomes and microsomes from mouse brain, although
the expression of human G2019S LRRK2 does not influence
their subcellular distribution. Dynamin GTPases form native
Figure 9. Mitochondrial dynamin GTPases are not required for LRRK2-induced toxicity in yeast. Yeast cells (BY4741 MATa), either WT or deletion mutants, were
transformed with (A) galactose-inducible or (B) constitutively expressing (p426GPD) high-copy expression constructs containing human LRRK2 (residues 1300–
2527). A corresponding empty vector (p426GAL1 or p426GPD) was used as a control. Cells were spotted onto SC-URA media containing glucose, galactose, glycerol
or ethanol as the sole carbonsource, as indicated, and incubated at 308C for up to 6 days. Shownare 5-fold serial dilutions (from left to right) startingwith equal numbers
of cells. Data are representative of two independently transformed clones for each plasmid.
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oligomeric complexes in mouse brain that are not altered by
modulating LRRK2 expression. Furthermore, the steady-state
levels of S-OPA1 are reduced in G2019S mutant PD brains,
whereas other dynamin GTPases are not altered by the G2019S
mutation. Dynamin-related GTPases but not Dnm1 tend to
promote the GTP-binding capacity of LRRK2, whereas oppos-
itely LRRK2 promotes the binding of Mfn1 to GTP. Dynamin
GTPases serve as modest substrates of LRRK2-mediated phos-
phorylation in vitro, especially Dnm1 and OPA1. In a yeast model,
endogenous dynamin GTPases that regulate mitochondrial
Figure 10. LRRK2 attenuates neurite shortening induced by Dnm1. (A) Primary cortical neurons were co-transfected with FLAG-tagged WT LRRK2, GFP-tagged
Dnm1 and DsRed-Max constructs at a molar ratio of 10:10:1 at DIV 3 and fixed at DIV 7. Fluorescent microscopic images indicate the co-labeling of cortical neurons
with combinations of FLAG-LRRK2, Dnm1-GFP and DsRed. DsRed images were pseudo-colored with ICA for neurite length measurements. Neuronal soma
(arrows) and axonal processes (arrowheads) are indicated. Scale bars: 400 mm. (B) Analysis of DsRed-positive neurites reveals a marked shortening of axonal pro-
cesses by Dnm1 expression alone, with a modest effect of WT LRRK2 expression alone, compared with control neurites (DsRed alone). Co-expression of WT LRRK2
and Dnm1 markedly attenuates the Dnm1-induced shortening of axonal processes. Bars represent axonal process length (mean+SEM) expressed as a percent of
DsRed alone (control) from ≥90 DsRed-positive neurons taken from at least three-independent experiments/cultures. ∗P , 0.05, ∗∗P , 0.01 or ∗∗∗P , 0.001 by
one-way ANOVA with Newman–Keuls post hoc analysis. (C) Western blot analysis with anti-FLAG, anti-GFP and anti-b-tubulin antibodies of cell extracts
derived from rat primary cortical neurons at DIV 7 transiently expressing FLAG-LRRK2 and Dnm1-GFP. Densitometric analysis reveals a strong trend (P ¼
0.059 by unpaired Student’s t-test) towards reduced Dnm1 levels in the presence of LRRK2. Graphs indicate LRRK2 (left) or Dnm1 (right) steady-state levels normal-
ized to b-tubulin levels, expressed as a percent of each protein alone (mean+SEM, n ¼ 3 experiments). n.s., non-significant.
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fission and fusion, as well as mitochondrial respiration, are
not required for LRRK2-mediated cellular toxicity. Alterna-
tively, however, LRRK2 functionally interacts with dynamin
GTPases in the regulation of neurite outgrowth in cultured
primary cortical neurons. LRRK2 attenuates impaired neurite
outgrowth induced by Dnm1 through a reduction in the levels
of Dnm1 protein. Drp1 and LRRK2 do not appear to functionally
interact upon neurite complexity, whereas LRRK2 can rescue
impaired neurite outgrowth induced by Mfn1. Collectively,
our data support the novel biochemical and selective functional
interaction of LRRK2 with members of the dynamin GTPase
superfamily that implicate LRRK2 in the regulation of mem-
brane dynamics involved in endocytosis and mitochondrial
function.
Our studies have previously implicated LRRK2 in regulating
endocytosis and exocytosis (14). The overexpression of human
LRRK2 in cultured neurons delayed synaptic vesicle endocyto-
sis and exocytosis, whereas LRRK2 expression in yeast cells dis-
rupted endocytic trafficking to the vacuole coincident with the
accumulation of autophagic vacuoles (14). A recent study has
Figure 11. LRRK2 does not influence neurite shortening induced by Drp1. (A) Primary cortical neurons were co-transfected with FLAG-tagged WT LRRK2, Myc-
tagged Drp1 (WT or K38A) and DsRed-Max constructs at a molar ratio of 10:10:1 at DIV 3 and fixed at DIV 7. Fluorescent microscopic images indicate the co-labeling
of cortical neuronswith combinations of FLAG-LRRK2, Myc-Drp1 and DsRed. DsRed images were pseudo-colored with ICA for neurite length measurements. Neur-
onal soma (arrows) and axonal processes (arrowheads) are indicated. Scale bars: 400 mm. (B) Analysis of DsRed-positive neurites reveals a marked shortening of
axonal processes by WT or K38A Drp1 expression alone, with a negligible effect of WT LRRK2 expression alone, compared with control neurites (DsRed
alone). Co-expression of WT LRRK2 and WT Drp1 fails to alter Drp1-induced shortening of axonal processes. Bars represent axonal process length (mean+
SEM) expressed as a percent of DsRed alone (control) from ≥90 DsRed-positive neurons taken from at least three-independent experiments/cultures. ∗∗∗P,
0.001 by one-way ANOVA with Newman–Keuls post hoc analysis. n.s., non-significant.
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shown that LRRK2 may control synaptic vesicle storage and mo-
bilization within the recycling pool through an unclear mechan-
ism although LRRK2 was found to putatively interact with a
number of proteins in synaptosomes involved in vesicular recyc-
ling including Dnm1 (24). Here, we describe a robust biochem-
ical interaction between LRRK2 and Dnm1 that is not influenced
by PD-associated mutations and most likely occurs at the cyto-
plasmic face of early endosomal vesicles. LRRK2 and Dnm1
do not appear to influence the GTPase activity of each other
insofar as GTP-binding capacity is unaffected, whereas Dnm1
serves as a modest substrate of LRRK2-mediated phosphoryl-
ation in vitro. Instead, LRRK2 and Dnm1 functionally interact
Figure 12. LRRK2 rescues impaired neurite outgrowth induced by Mfn1. (A) Primary cortical neurons were co-transfected with FLAG-tagged LRRK2 (WT or
G2019S), Myc-tagged Mfn1 and DsRed-Max constructs at a molar ratio of 10:10:1 at DIV 3 and fixed at DIV 7. Fluorescent microscopic images indicate the
co-labeling of cortical neuronswith combinations of FLAG-LRRK2, Myc-Mfn1and DsRed.DsRed imageswere pseudo-coloredwith ICA for neurite length measure-
ments. Neuronal soma (arrows) and axonal processes (arrowheads) are indicated. Scale bars: 400 mm. (B) Analysis of DsRed-positive neurites reveals a marked short-
ening of axonal processes by Mfn1 or G2019S LRRK2 expression alone, with a negligible effect of WT LRRK2 expression alone, compared with control neurites
(DsRed alone). Co-expression of G2019S LRRK2 and Mfn1 rescues the Mfn1-induced shortening of axonal processes, whereas WT LRRK2 partially rescues the
effects of Mfn1. Bars represent axonal process length (mean+SEM) expressed as a percent of DsRed alone (control) from ≥90 DsRed-positive neurons taken
from at least three-independent experiments/cultures. ∗∗P, 0.01 or ∗∗∗P, 0.001 by one-way ANOVA with Newman–Keuls post hoc analysis. n.s., non-significant.
(C) Western blot analysis with anti-FLAG, anti-myc and anti-b-tubulin antibodies of cell extracts derived from rat primary cortical neurons at DIV 7 transiently
expressing FLAG-LRRK2 and Myc-Mfn1. The levels of LRRK2 or Mfn1 are not altered when expressed alone or together. Blots are representative of
three-independent experiments.
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upon neurite complexity where gain (WT) or loss (K44A) of
Dnm1 function impairs neurite outgrowth that can be rescued
by expression of WT LRRK2 by reducing exogenous Dnm1
levels. The reduction of Dnm1 by WT LRRK2 could potentially
result from increased protein degradation or impaired transcrip-
tion/translation, or could reflect movement of Dnm1 into a bio-
chemically insoluble cellular compartment. However, we did
not observe any impact of G2019S LRRK2 expression on the
subcellular fractionation profile or steady-state levels of en-
dogenous Dnm1 in mouse and human brain nor could we
observe reduced Dnm1 levels by LRRK2 in HEK-293T cells
using exogenous proteins (refer to Figs 1A and G, 4C and 5).
We further explored the fate of exogenous Dnm1 in primary cor-
tical neurons and could demonstrate that WT LRRK2 expression
did not alter the detergent solubility of Dnm1 whereas prote-
asome or lysosome inhibition failed to recover Dnm1 protein
levels. Furthermore, protein turnover assays with cycloheximide
in cortical neurons did not reveal altered stability of Dnm1 in the
presence of LRRK2. Collectively, these observations suggest
that LRRK2 may influence the transcription and/or translation
of exogenous Dnm1, an effect that may be specific to cortical
neurons and/or exogenously expressed (rather than endogenous)
Dnm1. Taken together, the functional significance of the robust
biochemical interaction between LRRK2 and Dnm1 is unclear at
present, although it is possible that LRRK2 exists in a protein
complex with Dnm1 and exerts subtle effects on its function.
Our findings further support a connection of LRRK2 with the
regulation of endocytosis and membrane dynamics potentially
through Dnm1.
We have previously shown that a small proportion of en-
dogenous LRRK2 is associated with mitochondria by submito-
chondrial fractionation and electron microscopic analysis of
rodent brain (39). More recent studies have shown that
LRRK2 can regulate mitochondrial activity and morphology
in various cellular models and mutant LRRK2 transgenic
mice, although through an unclear mechanism (27,32,36–38).
Mutant LRRK2 has recently been shown to induce mitochon-
drial fission in a Drp1-dependent manner, potentially through
their direct interaction, and restoring mitochondrial morphology
by inhibiting fission attenuated LRRK2-mediated neuronal tox-
icity (49,50). These initial observations suggest that mitochon-
drial fission is required for LRRK2-induced neuronal damage.
Here, we further extend these previous studies by demonstrating
that LRRK2 commonly and robustly interacts with multiple
dynamin-related GTPases that regulate mitochondrial fission
and fusion, including Drp1, Mfn1, Mfn2 and OPA1. Dynamin-
related GTPases tend to enhance the GTP-binding capacity of
LRRK2, whereas LRRK2 reciprocally increases the level of
GTP-bound Mfn1. Increased GTP-binding capacity could
reflect a GTP-bound ‘active’ state of LRRK2 and Mfn1, or alter-
natively may suggest an impairment of GTP hydrolysis. GTPase
activity is critical for the membrane fusion activity of Mfn1 and
for the proper function of LRRK2 (23,54). Recombinant OPA1
(but not Drp1 or Mfn1) could serve as a modest substrate of
LRRK2-mediated phosphorylation in vitro but the impact of
phosphorylation on OPA1 function and whether and to what
degree this occurs in mammalian cells or tissues remains to be
clarified. Despite the effects of LRRK2 on the GTP-binding cap-
acity and phosphorylation of dynamin-related GTPases, the
subcellular distribution, steady-state levels and native oligo-
meric complexes of dynamin GTPases were not altered by
G2019S LRRK2 expression or LRRK2 deletion in the mamma-
lian brain. While human LRRK2-induced toxicity in yeast does
not require endogenous dynamin-related GTPase orthologs (i.e.
DNM1/Drp1, FZO1/Mfn or MGM1/OPA1) or mitochondrial
respiration, LRRK2 instead functionally interacts with Mfn1
but not Drp1 upon neurite complexity, with WT and G2019S
LRRK2 rescuing impaired neurite outgrowth induced by Mfn1
overexpression. These data suggest that excessive mitochondrial
fusion through Mfn1 overexpression promotes neuronal tox-
icity, and that potentially the profission effects of LRRK2
(with G2019S.WT) can reverse and mitigate these neurite
effects. It is also plausible that LRRK2 could directly interact
with and inactivate Mfn1 and thus inhibit its profusion effects,
as reflected by the increased levels of GTP-bound Mfn1
induced by LRRK2 that may reflect impaired GTPase activity.
We also observe weak phosphorylation of immunopurified
Mfn1 by G2019S LRRK2 in vitro and whether this occurs in
vivo and contributes to Mfn1 function is not yet clear. The lack
of functional interaction in yeast between human LRRK2 and
FZO1, an ortholog of mammalian Mfn1/2, could suggest that
FZO1 and Mfn1 are not entirely functionally conserved or that
the functional interaction of LRRK2 and Mfn1 is context de-
pendent and restricted to mammalian cells or neurons. It is inter-
esting to note that mitochondrial fragmentation and neuronal cell
death induced by mutant LRRK2 could be attenuated by inhibit-
ing mitochondrial fission via overexpression of dominant-
negative Drp1 (K38A) (50), suggesting that increasing mito-
chondrial fusion in the context of mutant LRRK2 is beneficial.
Our data would suggest that excessive mitochondrial fission
(via WT Drp1) or fusion (via WT Mfn1 or K38A Drp1) are in
general both detrimental in the context of neurite outgrowth.
The lack of an apparent functional interaction between
LRRK2 and Drp1 in these neurite outgrowth assays could
suggest that LRRK2 operates upstream of Drp1 in a common
pathway, where mitochondrial fission and impaired neurite out-
growth induced by Drp1 overexpression potentially supersedes
the requirement for LRRK2-mediated activation of Drp1. This
would be consistent with prior observations that LRRK2
induces mitochondrial fission and neuronal cell death in a
Drp1-dependent manner (49,50).
Collectively, our data support the broad and robust interaction
of LRRK2 with members of the dynamin GTPase superfamily in
mammalian cells. LRRK2 appears to exhibit distinct functional
effects upon individual dynamin GTPases. In particular, LRRK2
promotes the GTP-binding capacity of Mfn1 and rescues
impaired neurite outgrowth induced by Mfn1. Alternatively,
LRRK2 modestly phosphorylates OPA1 in vitro and the levels
of mature S-OPA1 are reduced in G2019S PD brains. Therefore,
the functional interaction of LRRK2 with dynamin GTPases is
rather complex but provides initial mechanistic support of a
role for LRRK2 in regulating membrane dynamics important
for mediating endocytosis and mitochondrial function (14,24–
27,32,36–38). Future studies are warranted to clarify the physio-
logical or pathological interaction of LRRK2 with dynamin
GTPases in animal models. Our findings suggest that dynamin
GTPases represent an important family of proteins implicated
in the biology and pathophysiology of LRRK2.
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MATERIALS AND METHODS
Ethics statement
For use of human brain tissue in this study, patients provided
written informed consent and approval for the consent procedure
and experiments were obtained from the NHS National Research
Ethics Committee of the UK (Approval No. 02/N093). All animal
experiments were approved by the SCAV (Service de la consom-
mation et des affaires veterinaires) in the Canton de Vaud, Switz-
erland (Animal authorization No. 2293), and conducted in strict
accordance with the European Union directive (2010/63/EU)
for the care and use of laboratory animals.
Animals
Mice and rats were maintained in a pathogen-free barrier facility
and exposed to a 12 h light/dark cycle with food and water pro-
vided ad libitum. Pregnant female Sprague-Dawley rats were
obtained from Charles River Laboratories (L’Arbresle Cedex,
France) and resulting P1 rats were used for preparation of
primary cortical neuronal cultures. LRRK2 knockout mice
with a deletion of exon 41 (57) were kindly provided by Drs.
Giorgio Rovelli and Derya Shimshek (Novartis Pharma AG,
Basel, Switzerland). Transgenic mice expressing full-length
human G2019S LRRK2 from a CMV-enhanced PDGFb pro-
moter (line 340) were described previously (32).
Expression plasmids, proteins and antibodies
Mammalian expression plasmids containing codon-optimized
FLAG-tagged full-length human LRRK2 (WT, R1441C, Y1699C
and G2019S) and LRRK2 deletion mutants were kindly provided
by Dr. Christopher Ross (Johns Hopkins University, Baltimore,
MD, USA). T1348N and D1994A mutations were introduced
into FLAG-tagged WT LRRK2 as previously described (21).
GFP-tagged human dynamin-1 (WT and K44A) plasmids were
kindly provided by Dr. Pietro De Camilli (Yale University,
New Haven, CT, USA) (58), and YFP-tagged ArfGAP1 was
provided by Dr. Jennifer Lippincott-Schwartz (National Insti-
tutes of Health, Bethesda, MD, USA) (59). As plasmid controls,
pcDNA3.1 (Invitrogen) and pDsRed-Max-N1 (Addgene #21718)
plasmids were obtained. HA-tagged mouse Dnm1 (#36263),
Dnm2 (#36264) and Dnm3 (#36265) and HA-tagged human
Dnm1 (#34682) plasmids were from Addgene. Myc-tagged human
Drp1 (WT and K38A), Mfn2 and OPA1, and mito-RFP plasmids
were kindly provided by Dr. Manuel Rojo (Universite´ Victor
Segalen, France). 10xMyc-tagged mouse Mfn1 (WT, #23212
and K88T, #26050) plasmids were obtained from Addgene. Ex-
pression plasmids containing human RFP-Rab5A (#14437) and
human GFP-Rab7A (#12605) were obtained from Addgene.
GST-tagged full-length human ArfGAP1 (residues 1–415),
Drp1 (residues 1–711), Mfn1 (residues 1–742) and OPA1 (resi-
dues 1–960) proteins were obtained from Novus Biologicals
(Littleton, CO, USA). The following antibodies were employed:
mouse monoclonal anti-FLAG-(M2), anti-FLAG-(M2)-perox-
idase, anti-b-tubulin (clone TUB 2.1), and rabbit polyclonal
anti-bIII-tubulin and anti-Mitofusin 2 (Sigma-Aldrich); mouse
monoclonal anti-GFP (clones 7.1 and 13.1), anti-c-myc (clone
9E10) and anti-c-myc-peroxidase, and rat monoclonal anti-HA
(clone 3F10) (Roche Applied Science); rabbit monoclonal
anti-LRRK2 (clone MJFF4/c81-8; Epitomics Inc.); mouse
monoclonal anti-LRRK2 (clone N241A/34; UC Davis/NIH
NeuroMab); mouse monoclonal anti-synaptophysin 1 (Synaptic
Systems); rabbit polyclonal anti-Dynamin-1 (ThermoFisher
Scientific); mouse monoclonal anti-OPA1 (clone 18/OPA-1)
and anti-DLP1/Drp1 (clone 8/DLP1) (BD Biosciences); rabbit
polyclonal anti-GST and anti-myc (Covance); peroxidase-
coupled anti-mouse, anti-rabbit and anti-rat IgG, light chain-
specific secondary antibodies (Jackson ImmunoResearch Inc.);
anti-rabbit, anti-mouse and anti-rat IgG coupled to AlexaFluor-
488, -546 and -633 (Invitrogen).
Cell culture and transient transfection
HEK-293T and SH-SY5Y neuroblastoma cells were maintained
in Dulbecco’s modified Eagle’s media supplemented with 10%
fetal bovine serum and 1× penicillin/streptomycin at 378C in
a humidified atmosphere containing 5% CO2. Cells were trans-
fected with plasmid DNAs using X-tremeGENE HP DNA
Transfection Reagent (Roche Applied Science). Cells were rou-
tinely harvested at 48–72 h posttransfection for biochemical
assays.
Co-immunoprecipitation assays and western blotting
Co-IP assays were conducted as previously described (21).
Briefly, HEK-293T cells were harvested in IP buffer (1× PBS,
pH 7.4, 1% Triton X-100, 1× phosphatase inhibitor cocktail 2
and 3 [Sigma-Aldrich], 1× Complete Mini Protease Inhibitor
cocktail [Roche Applied Sciences]) and incubated overnight at
48C with Protein G-Dynabeads (Invitrogen) pre-coupled with
mouse anti-FLAG-M2 (5 mg; Sigma-Aldrich), rat anti-HA
(2 mg; Roche Applied Science), mouse anti-myc (5 mg; Roche
Applied Science) or mouse anti-GFP (1 mg; Roche Applied
Science) antibodies. Dynabead complexes were washed with
IP buffer and proteins eluted at 708C for 10 min in Laemmli
sample buffer (Bio-Rad) containing 5% 2-mercaptoethanol.
IPs and input lysates (1% total) were resolved by SDS–PAGE,
transferred to Protran nitrocellulose (0.2 mm; Perkin Elmer),
and subjected to western blotting with appropriate primary and
secondary antibodies. Proteins were visualized by enhanced
chemiluminescence (ECL; GE Healthcare) on a FujiFilm LAS-
4000 Luminescent Image Analysis system. LabImage 1D soft-
ware (Kapelan Bio-Imaging Solutions) was used for quantitation
of protein levels by densitometric analysis.
For in vivo co-IP, protein extracts were prepared from whole
brains of adult WT and LRRK2 knockout mice (with targeted
deletion of exon 41 of the LRRK2 gene (57); kindly provided
by Drs. Giorgio Rovelli and Derya Shimshek, Novartis Pharma
AG, Basel, Switzerland) by homogenization in TNE buffer
(10 mM Tris–HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 0.5%
NP-40, phosphatase inhibitor cocktails 2 and 3 [Sigma-Aldrich],
Complete Mini protease inhibitor cocktail [Roche Applied
Sciences]). Protein concentration was determined by BCA
assay (Pierce Biotechnology, Rockford, IL, USA). Brain ex-
tracts (20 mg protein) were combined with 50 ml Protein
G-Dynabeads (Invitrogen) pre-incubated with mouse monoclo-
nal anti-LRRK2 (5 mg; N241A/34; NeuroMab) antibody fol-
lowed by overnight incubation at 48C. Dynabead complexes
were sequentially washed twice with TNE buffer and twice
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with TBS buffer (10 mM Tris–HCl, pH 7.4, 150 mM NaCl).
Immunoprecipitates were eluted by heating at 708C for
10 min, resolved by SDS–PAGE and subjected to western blot
analysis.
Immunocytochemistry and confocal microscopy
SH-SY5Y cells and rat primary cortical neurons were processed
for immunocytochemistry as previously described (21). Briefly,
transfected cells were fixed in 4% paraformaldehyde (PFA) and
incubated with combinations of mouse anti-FLAG, rat anti-HA
or rabbit anti-myc antibodies together with anti-mouse IgG-
AlexaFluor-546 or -633, anti-rabbit IgG-AlexaFluor-488 or
-633 or anti-rat IgG-AlexaFluor-488 antibodies and stained
with DAPI. Images were acquired using a Zeiss LSM 700 in-
verted confocal microscope (Carl Zeiss AG) with a Plan-
Apochromat ×63/1.40 oil objective in x, y and z planes.
Images were subjected to deconvolution using HuygensPro soft-
ware (Scientific Volume Imaging). Representative images are
taken from a single z-plane at 0.1 mm thickness. To provide a
relative assessment of co-localization, images were minimized
for background noise at acquisition and subjected to deconvolu-
tion. Images were analyzed using a co-localization threshold
plugin in NIH ImageJ to calculate the intensity of pixels that
overlap between the two fluorescent channels. ImageJ automat-
ically sets a threshold for each channel and renders a gray scale
8-bit image containing only those pixels above the threshold
level. A scatterplot of pixel intensity for the two channels is
plotted on x- and y-axes with a linear regression fit, from which
Pearson’s correlation coefficient (Rcoloc) values are calculated
for the two channels ranging from 0 (random co-localization) to
1 (perfect co-localization). A value of 21 indicates a perfect ex-
clusion of the two signals.
Size-exclusion chromatography
Size-exclusion chromatography was conducted as described
previously using an Akta-FPLC system (Amersham Biosciences)
(44). Briefly, cleared brain extracts prepared in lysis buffer (0.1%
Triton X-100, 1× PBS, pH 7.4, 1× Complete Protease Inhibitor
cocktail [Roche Applied Science]) derived from whole brains of
adult WT and LRRK2 KO mice were injected for FPLC on a
Superdex 200 10/300 GL column (Amersham Biosciences).
The elution volumes of standards were 9 ml for thyroglobulin
(669 kDa), 10.5 ml for ferritin (440 kDa), 12.5 ml for aldolase
(158 kDa) and 15.5 ml for conalbumin (75 kDa). Fractions
(0.5 ml) were analyzed by SDS–PAGE and western blotting
with anti-Dnm1, anti-Drp1, anti-b-tubulin and anti-LRRK2
(N241A/34) antibodies.
Native PAGE
Brain extracts were prepared from cerebral cortex tissue pooled
from two adult WT and LRRK2 KO mice, or human G2019S
LRRK2 transgenic and non-transgenic mice by homogenization
in TEVP buffer (10 mM Tris–HCl, pH 7.4, 5 mM NaF, 1 mM
Na3VO4, 1 mM EDTA, 1 mM EGTA) containing 320 mM sucrose.
Equivalent extracts were resolved on Native-PAGE 3–12%
Bis–Tris gradient gels (Invitrogen) and blots were subjected
to western blotting with anti-Dnm1, anti-Drp1, anti-Mfn2,
anti-OPA1 and anti-LRRK2 antibodies. In parallel, equivalent
extracts were analyzed by SDS–PAGE and western blotting.
Subcellular fractionation of mouse brain
Subcellular fractionation was conducted by differential centrifu-
gation as described previously (21,44) using cerebral cortex
tissue pooled from two adult WT and LRRK2 KO mice, or
human G2019S LRRK2 transgenic and non-transgenic mice.
Fractions generated include: total homogenate (H), nuclear/
whole cell (P1), soluble cytosolic (S1, S2 and S3), heavy mem-
brane (P2), light membrane/microsomes (P3), synaptosomal
membrane (LP1) and cytosolic (LS1), synaptic vesicle-enriched
(LP2) and cytosolic (LS2) fractions. Equal quantities of each
fraction as determined by BCA assay (Pierce Biotechnology)
were assessed by western blotting with antibodies labeling
mitochondria (Mfn2 and OPA1; P2 and LP1) and synapto-
somes/synaptic vesicles (synaptophysin 1; P2, P3, LP1 and
LP2) subcellular compartments.
Human brain tissue and fractionation
Human tissue for these studies was obtained from the archive
at Queen Square Brain Bank (QSBB) as previously reported
(44,60). Flash-frozen frontal cortex tissue derived from four
G2019S PD, four idiopathic PD and four control subjects was
employed. Table 1 lists the details of these human subjects.
Tissue homogenates (10%, w/v) were prepared in homogeniza-
tion buffer (20 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1× Com-
plete Protease Inhibitor cocktail [Roche Applied Science], 1×
phosphatase inhibitor cocktail [Roche Applied Science]) as pre-
viously described (44,60). Equivalent proteins were resolved on
3–8% Tris–acetate SDS–PAGE gradient gels (Invitrogen), and
blots were subjected to western blotting with anti-Dnm1,
anti-Drp1, anti-Mfn2, anti-OPA1 and anti-b-tubulin antibodies.
GTP-binding assay
HEK-293T cell extracts were prepared in buffer A (1× PBS, pH
7.4, 1% Triton X-100, 1× phosphatase inhibitor cocktail 2
and 3 [Sigma-Aldrich], 1× Complete Mini Protease Inhibitor
Table 1. Clinical details of human brain tissue
Subject Gender Age (years) PMD (h) Pathology
G2019S 1 F 80 44.4 Limbic
G2019S 2 F 81 15 Limbic
G2019S 3 F 84 32.2 Limbic
G2019S 4 F 72 24.55 Limbic
iPD 1 F 69 52.5 Limbic
iPD 2 M 70 61.2 Limbic
iPD 3 F 87 47.45 Limbic
iPD 4 M 75 48 Limbic
Control 1 F 85 37 N/A
Control 2 M 93 112 N/A
Control 3 F 91 98.5 N/A
Control 4 M 87 36 N/A
iPD, idiopathic Parkinson’s disease; Limbic, limbic subtype of Lewy body
pathology according to McKeith consensus criteria for the classification of
DLB∗∗ (61); N/A, non-applicable; PMD, postmortem delay.
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Cocktail [Roche Applied Science]). Equivalent extracts were
incubated with 25 ml of guanosine 5′-triphosphate-agarose
(Sigma-Aldrich) by rotating for 2 h at 48C. Agarose beads were
washed three times with buffer A and once with 1× PBS, and
GTP-bound proteins were eluted in Laemmli sample buffer con-
taining 5% 2-mercaptoethanol and heating at 708C for 10 min.
GTP-bound fractions and input lysates (1% total) were resolved
by SDS–PAGE and subjected to western blotting with anti-
FLAG, anti-GFP and anti-myc antibodies.
In vitro radioactive kinase assays
Kinase assays were conducted essentially as previously described
(20,21). HEK-293T cell extracts expressing full-length Myc-
Drp1, Myc-Mfn1, Myc-Mfn2, Myc-OPA1, Dnm1-GFP or
ArfGAP1-YFP were subjected to IP with Protein G-Dynabeads
(Invitrogen) precoupled to anti-myc (5 mg) or anti-GFP (1 mg)
antibodies and extensive washing for ‘on-bead’ kinase assays.
Soluble recombinant full-length FLAG-LRRK2 proteins were
purified from cell extracts by IP with anti-FLAG-(M2)-agarose
(Sigma-Aldrich) and eluted with 3xFLAG peptide. In some
assays, recombinant full-length GST-tagged Drp1, Mfn1,
OPA1 or ArfGAP1 proteins (1 mg/reaction; Novus Biologicals)
were used together with soluble FLAG-LRRK2 proteins. A frac-
tion of each soluble or on-bead protein preparation was routinely
resolved by SDS–PAGE and stained with Coomassie G-250
(Bio-Rad) to confirm protein purity. Kinase reactions were
performed with equivalent quantities of LRRK2 or substrate
proteins in kinase buffer (25 mM Tris–HCl, pH 7.5, 5 mM
b-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3VO4,
10 mM MgCl2) in the presence of [
33P]-g-ATP (2 mCi/reaction;
Perkin Elmer) and 5 mM cold ATP (Sigma-Aldrich) at 308C for
1 h in a final volume of 25 ml. Reactions were terminated with
4× Laemmli buffer and heating at 958C for 10 min. Prior to ter-
mination, kinase reactions containing soluble LRRK2 and
‘on-bead’ substrate proteins were separated. Reactions samples
were resolved on 3–8% Tris–acetate or 4–16% Tris–glycine
SDS–PAGE gradient gels (Invitrogen) and transferred to PVDF
membranes. Incorporated radioactivity was detected using a
Phosphor imaging system and membranes were subsequently
probed with anti-FLAG, anti-myc, anti-GFP or anti-GST anti-
bodies to confirm equal protein loading of LRRK2 and each sub-
strate. Relative substrate phosphorylation levels were determined
by densitometric analysis of 33P signals normalized to substrate
protein levels on western blots.
Yeast growth assays
A WT human LRRK2 cDNA fragment (residues 1300–2527)
was amplified from a pYES2/CT-LRRK2 vector (14) by PCR
to incorporate a 5′ optimal yeast Kozak sequence (AAAA
ATGTCT) and a 3′ in-frame C-terminal V5 tag and stop
codons. Blunt-end PCR products were first cloned into a direc-
tional pENTR/D-TOPO entry vector, sequenced to confirm
their integrity and subjected to recombination with the Gateway-
compatible destination vectors, p426GAL1-ccdB or p426GPD-
ccdB (2 mm ori, URA3; Addgene), for high-copy expression
in yeast cells. Yeast haploid parental strain BY4741 (MATa,
his3D1, leu2D0, met15D0 and ura3D0) and deletion strains
(Ddnm1, Dmdv1, Dmdv2, Dfzo1, Dmgm1 and Dugo1) on a
BY4741 genetic background were obtained from Open Bio-
systems (ThermoFisher Scientific). Yeast manipulations were
performed, and media were prepared using standard procedures.
Yeast cells were transformed with plasmids using a standard
lithium acetate procedure. Yeast cells carrying high-copy
(2 mm) expression plasmids (p426GAL1-LRRK2, p426GPD-
LRRK2, p426GAL1 or p426GPD) were routinely grown in syn-
thetic complete media lacking uracil (SC-URA) containing
glucose (2% dextrose). Yeast cells were diluted in dH2O and nor-
malized for OD600 nm, serially diluted (5-fold) and spotted onto
plates containing solid media (SC-URA) with 2% glucose, gal-
actose, glycerol or ethanol as the sole carbon source. Cells
were grown at 308C for up to 6 days before imaging.
Primary neuronal cultures and neurite length assays
Primary cortical neurons were prepared from Sprague-Dawley
P0–P1 rats by stereoscopically isolating the cerebral cortices
and dissociation by digestion in media containing papain
(20 U/ml; Sigma-Aldrich) and mechanical trituration. Cells
were plated in 35 mm dishes on glass cover slips coated with
poly-D-lysine (20 ng/ml; BD Biosciences) and mouse laminin
(33 mg/ml; Invitrogen) and maintained in Neurobasal media
containing B27 supplement (2%, w/v), L-glutamine (500 mM)
and penicillin/streptomycin (100 U/ml) (Invitrogen).
Neurons were transfected at DIV 3 with combinations of
FLAG-LRRK2, Myc-Drp1/Myc-Mfn1/Dnm1-GFP and DsRed-
Max plasmids at a 10:10:1 DNA molar ratio (5 mg DNA total/
dish) using Lipofectamine 2000 reagent (Invitrogen). Cultures
were fixed at DIV 7 with 4% PFA and subjected to immunocyto-
chemistry with mouse anti-FLAG antibody (Sigma-Aldrich) and
rabbit anti-myc antibody (Covance), and anti-mouse IgG-
AlexaFluor-633 and anti-rabbit IgG-AlexaFluor-488 antibodies
(Invitrogen). Fluorescent images were acquired using an EVOS
inverted fluorescent digital microscope (Advanced Microscopy
Group) with a ×10 objective. DsRed images were pseudo-
colored with ICA1 using NIH ImageJ software to improve the
contrast of neuritic processes, and used for neurite length mea-
surements. The length of DsRed-positive axonal processes
from single-labeled (DsRed alone), double-labeled (DsRed/
FLAG, DsRed/Myc or DsRed/GFP) or triple-labeled (DsRed/
FLAG/Myc or DsRed/FLAG/GFP) cortical neurons were mea-
sured using the line tool function of ImageJ by an investigator
blinded to each condition. Only neurons that had extended neur-
ites were measured, whereas neurons without processes were
excluded from the analysis. For each experiment, axonal pro-
cesses from ≥30 DsRed-positive neurons randomly sampled
across five cover slips were measured, and repeated for at least
three-independent experiments/cultures.
Statistical analyses
Data were analyzed by one-way ANOVA with Newman–Keuls
post hoc analysis for comparison of multiple data groups, or by
two-tailed unpaired Student’s t-test for pairwise comparisons,
as indicated. P, 0.05 was considered significant.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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